ProPhase Labs (NYSE: PRPH) — Company Overview, News & Financial Data
ProPhase Labs focuses on innovative diagnostics and biotechnology solutions to enhance healthcare outcomes and efficiency.
ProPhase Labs
ProPhase Labs (NASDAQ:PRPH) is a diversified medical science and technology company with a focus on developing innovative solutions across diagnostics, genomics, and biotechnology spaces. The company is committed to leveraging its expertise in molecular biology to create advancements in disease detection and analysis, aiming to improve patient outcomes and healthcare efficiency. Projects under ProPhase Labs' umbrella include the development of advanced diagnostic tests for infectious diseases and genomic testing services that provide critical insights for personalized medicine. Objectives for the company revolve around expanding its market presence through cutting-edge research, strategic partnerships, and the acquisition of complementary technologies to address pressing health challenges.
Snapshot
Operations
Products and/or services of ProPhase Labs
- DNA testing services tailored for individual genetic markers ensuring personalized healthcare and wellness insights.
- Rapid test kits for COVID-19, providing quick and reliable detection of the virus.
- Over-the-counter cold remedy formulation designed to reduce symptom severity and duration.
- Genetic testing kits for consumer use, offering insights into ancestry, traits, and health predispositions.
- Immune support supplements, leveraging scientific research to boost the body's natural defenses.
- Contract manufacturing services, offering comprehensive solutions from product development to market readiness for healthcare products.
ProPhase Labs executive team
- Mr. Ted William KarkusChairman & CEO
- Mr. Jason KarkusPresident of Nebula Genomics
- Mr. Kevin QuinnChief Product Officer of Nebula Genomics
Latest news about ProPhase Labs
Dividend history
Dividends per share paid by ProPhase Labs, by financial year.
| Financial year | Interim | Final | Special | Total |
|---|---|---|---|---|
| FY2021 | — | $6.0000 | — | $6.0000 |
| FY2020 | — | $3.0000 | — | $3.0000 |
| FY2019 | $2.5000 | — | — | $2.5000 |
| FY2018 | — | $2.5000 | — | $2.5000 |
| FY2017 | — | $20.0000 | — | $20.0000 |
Key financials
Reported results for ProPhase Labs, in USD.
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 4.3M | -18M | -14.7M | |
| 6.8M | -38.6M | -53.4M | |
| 44.4M | -21.6M | -16.8M | |
| 122.6M | 23.6M | 18.5M |